



Media Release

January 12, 2026

Idorsia to present at J.P. Morgan 2026 Healthcare Conference

Allschwil, Switzerland – January 12, 2026

Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 10:30 am PST / 7:30 pm CET. The conference will take place at the Westin St. Francis hotel in San Francisco, USA.

Dr Gupta will share how, with two products entering value-acceleration phase and an innovative pipeline poised to deliver the next generations of breakthrough medicines, Idorsia is on a path to profitability and growth.

Follow this [link](#) to access the live audio stream. A replay will be available on the company website after the event under Investors / News & Events.

Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “Idorsia represents a rare combination: A commercial-stage pharma company with two products that have blockbuster potential and a highly innovative pipeline of first- or best-in-class medicines. We have a clear path to making QUVIVIQ the standard of care in insomnia – unlocking its value, and we are actively engaging in discussions to maximize the value of TRYVIO/JERAYGO and change the treatment landscape of uncontrolled hypertension with the only medication targeting the endothelin system. We also have plans to advance our pipeline, leading where we can and partnering where we should. In 2026, Idorsia will continue to build toward sustainable profitability and long-term growth, creating meaningful value for patients and shareholders alike.”

The presentation will cover the highlights of the strong operational progress the company achieved in 2025 and outline the areas of focus for 2026:

Highlights in 2025

- **QUVIVIQ** sales surge – remaining on track to hit sales guidance of around CHF 130 million
 - QUVIVIQ **global expansion** continues
- **TRYVIO 1st and only** systemic hypertension therapy to target a new pathway in decades
 - Real-world prescriber feedback confirms PRECISION-like **double-digit BP reductions** and great tolerability across patient groups
- **Clinical validation** for Idorsia's revolutionary drug-like synthetic glycan **vaccine** technology
- Initiation of proof-of-concept / mechanism trial with **CCR6 antagonist**
- Completed debt restructuring
- New financing from equity and debt investors extended the cash runway into 2028

Areas of focus in 2026

- Continued global expansion of **QUVIVIQ** through partnerships
- Adoption of new sales and distribution models for **QUVIVIQ**
- Support potential **QUVIVIQ** descheduling in the US
- **Share results for daridorexant** Phase 2 in pediatric insomnia
- Initiate **daridorexant daytime functioning** US label-enabling study
- Advance discussions to maximize the value of **TRYVIO/JERAYGO**
- Advance **lucerastat for Fabry Disease** registration
- Advance our Phase 2 proof-of-concept immunology portfolio

Notes to the editor

About Idorsia

The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:

George Thampy
Senior Vice President, Head of Investor Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com - media.relations@idorsia.com - www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "intend", "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.